Empajent 25/5 is an oral fixed-dose combination tablet containing **Empagliflozin (an SGLT2 inhibitor)** and **Linagliptin (a DPP-4 inhibitor)**, produced by Alhavi Pharmaceutical — the first manufacturer of this combination in Iran.
It is used to control blood glucose levels in adults with type 2 diabetes mellitus.
The complementary mechanisms of the two ingredients enhance glycemic control — Empagliflozin promotes urinary glucose excretion, while Linagliptin increases insulin secretion and reduces hepatic glucose production.
Empajent is available in two strengths: **10/5 mg** and **25/5 mg** tablets.
Empajent 25/5 (Empagliflozin + Linagliptin)
Dosage form: Tablet
Empajent 25/5 is indicated for:
• Control of blood glucose levels in adults with type 2 diabetes mellitus who require combination therapy with Empagliflozin and Linagliptin
• Can be used as an adjunct to diet and exercise, alone or in combination with other antidiabetic agents
This dual-action formula provides complementary glycemic control through renal glucose excretion and enhanced insulin secretion.
• Recommended dose: **25/5 mg once daily**
• Can be taken in the morning, **with or without food**
• Swallow the tablet whole with water — do not crush or chew
• Continue diet and exercise as advised by your healthcare provider
• Use under medical supervision, particularly in patients with kidney or liver impairment